



World Leading Pharmaceutical Research Acquisition Opportunity



Premium Facility and Capabilities

- ▶ The IRBM (www.irbm.it) is a premier Merck & Co., Inc. pharmaceutical research facility
- ▶ Team of successful, highly experienced research scientists (currently 150 in total)
- ▶ Therapeutic focus on Oncology and Virology
- ▶ Core competencies in small molecules and biologicals discovery, including medicinal chemistry, peptide chemistry, antibody discovery, *in vitro* screening, cell biology, *in vivo* biology and DMPK
- ▶ DMPK capabilities include small molecule, peptide and protein molecule studies in rodents, dogs and primates
- ▶ Modern site, with the majority of the buildings constructed post-2000
- ▶ Advanced research facilities, with state-of-the-art automation
- ▶ Located near Rome, in the Lazio region of Italy
- ▶ Potential access to regional, governmental and EU grants, plus tax credits to support research and business in Lazio
- ▶ Collaborations with vibrant local academic community
- ▶ Experienced in the provision of research services to third parties (non-Merck)

Outstanding Research Productivity Record

The facility has been exceptionally productive for Merck & Co., Inc. generating:

- ▶ 2 launched products in the last 4 years (including ISENTRESS, the first approved HIV integrase inhibitor, winner of the Prix Galien USA 2008 award for Best Pharmaceutical Agent, with projected annual sales of \$1.5 B by 2014)
- ▶ More than 20 compounds selected for human Phase I studies in the last 8 years
- ▶ More than 5 compounds currently in Phase I and II clinical trials

To date, IRBM research has resulted in 90 patents (granted or applied for). A portion of this IP may be transferred to the new owner.

The current owner wishes to divest the facility (whole or in part) by 30th September 2009.

For further information, please contact:

Kevin Bottomley
Senior Principal
PharmaVentures Ltd, Magdalen Centre,
Oxford Science Park, Oxford OX4 4GA, UK
Phone: +44 (0) 7931 144079
Fax: +44 (0) 1865 784178
kevin.bottomley@pharmaventures.com